Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Nanexa: One Dose is Enough

2020-04-14

07:20

JS

Jakob Svensson

Redeye initiates coverage of Nanexa, an early-stage drug delivery company able to enhance compounds already on the market. Our confidence in management’s ability to commercialise its technology platform underpins our positive stance, while the share’s undemanding valuation after a recent capital raise provides an attractive entry point.

Disclosures and disclaimers